Form 4: Envista Diagnostics President Boosts Notional Stock Holdings

Envista Holdings Corp's President of Diagnostics, Robert Befidi, acquired 998 notional shares in the company's deferred contribution program at $23.47 per share.

Summary

• Robert Befidi, President, Diagnostics at Envista Holdings Corp (NVST), acquired 998 notional shares of Envista common stock.
• The acquisition occurred on February 1, 2026, as part of the company's deferred contribution programs Envista Stock Fund.
• The notional shares were acquired at a price of $23.47 per share.
• Following this transaction, Befidi beneficially owns 2,149 notional shares in the Envista Stock Fund.
• These shares represent the company's annual contribution to Befidi's Excess Contribution Program (ECP) account.
• Vesting for matching contributions in the ECP occurs on the first anniversary after being credited, while non-elective contributions vest on the later of the first anniversary or three years of service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine executive compensation disclosure, slightly positive due to increased insider alignment, but not indicative of significant operational changes or market-moving news.

Positives

• An insider, Robert Befidi, increased his beneficial ownership in the company's stock fund, indicating continued alignment with shareholder interests.
• The acquisition is part of a company contribution program, reflecting a benefit provided to a key executive.

Risks

• The shares are "notional" and "unfunded," meaning they represent a promise to deliver shares or cash equivalent in the future, subject to the company's financial health and the terms of the ECP.
• Vesting conditions apply to the contributions, meaning the executive does not immediately have full ownership rights to the shares.

Future Outlook

The filing indicates future vesting events for the acquired notional shares, with matching contributions vesting on the first anniversary and non-elective contributions vesting on the later of the first anniversary or three years of service.

Industry Context

StockSavvy.ai notes that executive participation in deferred compensation plans, particularly those tied to company stock, is a common practice across industries. It aligns executive incentives with long-term shareholder value, a standard corporate governance principle.

Comparison to Industry Standards

• This type of executive compensation structure, involving deferred stock units or notional shares with vesting schedules, is a standard practice in publicly traded companies, particularly in the healthcare and medical device sectors where Envista operates.
• Companies like Dentsply Sirona (XRAY) or Align Technology (ALGN) often utilize similar long-term incentive plans to retain and motivate key executives.
• The specific value of 998 shares at $23.47 is specific to this executive's compensation plan and not directly comparable to other companies' specific grants without more context on total compensation.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholders through stock ownership, albeit notional and subject to vesting.
• Employees: No direct impact on general employees, but reflects executive compensation practices.

Next Steps

• Vesting of matching contributions on the first anniversary after being credited.
• Vesting of non-elective contributions on the later of the first anniversary after being credited or three years of service with Envista.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event where an insider acquired notional shares as part of a deferred contribution program. It does not contain information that would fundamentally alter the investment thesis for Envista Holdings Corp. While it shows continued executive alignment, it's not a strong signal for a buy or sell decision. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Envista Holdings Corp, NVST, Form 4, Insider Trading, Beneficial Ownership, Deferred Compensation, Stock Fund, Executive Compensation, Robert Befidi, Diagnostics